Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury

Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been iden...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 24; no. 23; p. 2692
Main Authors Marinho, H Susana, Marcelino, Paulo, Soares, Helena, Corvo, Maria Luísa
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2018
Subjects
Liver transplant
RNA interference
drug delivery
ischaemia-reperfusion injury
small interference RNA
liposomes
Online AccessGet more information

Cover

More Information
Summary:Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach. This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation. We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs. We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects. siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
ISSN:1873-4286
DOI:10.2174/1381612824666180807124356